undamentalytics Newsletter
Sign in

Corbus Pharmaceuticals Holdings, Inc. insider trading

Every open-market purchase and sale by Corbus Pharmaceuticals Holdings, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $126,243 3 trades by 1 insider 3 months later: median +52.6% (+51.5% vs S&P 500) Insider sales, 5 years $3.4M 18 trades by 10 insiders 3 months later: median +15.1% (+9.7% vs S&P 500)
Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Corbus Pharmaceuticals Holdings, Inc.’s insiders pay?

From November 26, 2014 to August 12, 2026, 16 insiders reported 67 open-market purchases and 6 sales not made under a pre-set plan in Corbus Pharmaceuticals Holdings, Inc. Twelve months after each purchase was reported, the shares were −24.5% against the S&P 500 on average (median −17.8%), over 37 purchases with a full year of prices; 19% beat the index. After sales, the shares moved +31.5% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on September 9, 2016 into $3,540 by November 2, 2026, −9.8% a year. It held shares 59% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $26,504 (+10.1% a year), and held throughout $41,743 (+15.2%).

$0$20.0k$40.0k 201620182020202220242026 $41.7k$26.5k$3.5k
Copying Corbus Pharmaceuticals Holdings, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Corbus Pharmaceuticals Holdings, Inc.'s insiders from September 9, 2016, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 59% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
White Barbara Chief Medical Officer 20 −17.5% (8) 25% 0 — March 18, 2020
Moran Sean F. Chief Financial Officer 17 −18.3% (9) 22% 0 — March 14, 2019
Hochman David P Director 7 −15.6% (7) 29% 0 — March 18, 2019
Catlin Avery W Director 5 −25.1% (2) 0% 0 — May 12, 2017
Cohen Yuval Chief Executive Officer 5 −16.6% (4) 25% 0 — March 17, 2020
Chen Bihua 10% owner 2 −92.3% (2) 0% 1 — December 15, 2025
Discordia Robert Paul Chief Operating Officer 3 −1.1% (1) 0% 0 — March 18, 2020
Smethurst Dominic Chief Medical Officer 0 — — 3 +31.5% (1) March 4, 2026
Gupta Renu Director 2 — — 0 — August 19, 2015
Saxena Nishant C Chief Business Officer 2 — — 0 — August 12, 2026
Burstein Sumner 10% owner 0 — — 1 — July 17, 2015
Cormorant Asset Management, LP 10% owner 1 −82.3% (1) 0% 0 — February 6, 2024
Cormorant Global Healthcare Master Fund, LP 10% owner 1 −60.4% (1) 0% 0 — September 24, 2024
Hodgson Ian Chief Operating Officer 0 — — 1 — February 4, 2026
Millian Craig Stuart Chief Commercial Officer 1 −29.6% (1) 0% 0 — March 15, 2019
Panayiotopoulos Paris Director 1 −17.4% (1) 0% 0 — November 17, 2017

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Corbus Pharmaceuticals Holdings, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Corbus Pharmaceuticals Holdings, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 5 buying crowds with six months of prices, it averaged −12.7% against the index. After 1 selling crowd, +14.6%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
February 27, 20263 selling−18.3%+14.6%not yet
February 29, 20242 buying+31.1%+77.1%−93.1%
March 31, 20203 buying+40.0%−92.4%−118.6%
March 29, 20194 buying−4.5%−33.6%−15.2%
March 29, 20183 buying−19.8%+6.6%+9.3%
March 31, 20172 buying−26.7%−21.0%−43.6%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Corbus Pharmaceuticals Holdings, Inc. · Funds · Politicians